证券日报网讯1月7日，嘉应制药（002198）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司合并普通账户和融资融券信用账户持有人数为24806户。 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

证券之星消息，12月25日中药板块较上一交易日上涨0.35%，万邦德领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。中药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002082 | 万邦德 | 3097.69万 | 10.85% | -62.47万 | -0.22% | -3035.22万 | -10.63% | | 6660000 | 华润三九 | 1626.63万 | 8.76% | 105.06万 | 0.57% | -1731.69万 | -9.33% | | 002198 | 嘉应制药 | 1625.31万 | 14.00% | -658.57万 | -5.67% | -966.73万 | -8.33% | | 600518 | 康美药业 | 1573.51万 | 11.34% | -1158.65万 | -8.35% | ...

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. has launched an international promotion plan centered on its classic Hakka medicine product "Shuangliao Houfeng San" during a promotional event in Hong Kong, aiming to promote Hakka medicine to global Hakka communities [1][18]. Group 1: Cultural Significance and Product Overview - The cultural significance of Hakka medicine is highlighted, emphasizing its unique system formed over centuries by integrating traditional Chinese medicine wisdom and regional experiences, with "Shuangliao Houfeng San" being a prime example [3][20]. - The product adheres to principles of using authentic medicinal materials and precise preparation, establishing a comprehensive quality control system, thus representing both Hakka cultural heritage and clinical efficacy [3][20]. Group 2: Strategic Initiatives and Collaborations - The choice of Hong Kong as the initial launch site leverages its position as a cultural crossroads and its robust pharmaceutical regulatory framework to facilitate global outreach for Hakka medicine [4][21]. - A strategic cooperation agreement was signed between Jiaying Pharmaceutical and the Global Value Investment Association to collaboratively develop an international innovation framework for Hakka medicine [11][28]. Group 3: Market Development and Future Plans - The company presented a detailed analysis of its sales policies and international expansion plans, focusing on the cultural value, brand rejuvenation, and market models for "Shuangliao Houfeng San" in global health scenarios [7][24]. - Future collaborations will focus on optimizing distribution channels, enhancing brand building, and promoting product innovation, aiming for a win-win outcome through resource integration between Guangdong and Hong Kong [9][26]. Group 4: Industry Insights and Recommendations - Experts discussed the implementation paths and challenges of the Hakka medicine internationalization plan, providing actionable suggestions for product promotion, competitive differentiation, and research topics [12][29]. - The event served as a platform for the systematic international dissemination of Hakka medicine culture, with Jiaying Pharmaceutical positioning "Shuangliao Houfeng San" as a cultural carrier to showcase the unique value of traditional Chinese medicine on a global stage [16][33].

证券之星消息，12月22日中药板块较上一交易日下跌0.23%，嘉应制药领跌。当日上证指数报收于 3917.36，上涨0.69%。深证成指报收于13332.73，上涨1.47%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流出1.45亿元，游资资金净流入1.39亿元，散户资金净流 入668.25万元。中药板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日中药板块主力资金净流入8839.85万元，游资资金净流出1.78亿元，散户资金净 流入8992.67万元。中药板块个股资金流向见下表： 证券之星消息，12月17日中药板块较上一交易日上涨0.59%，嘉应制药领涨。当日上证指数报收于 3870.28，上涨1.19%。深证成指报收于13224.51，上涨2.4%。中药板块个股涨跌见下表： ...

Market Overview - The Shanghai Composite Index closed at 3871.44 points, above the annual line, with an increase of 1.22% [1] - The total trading volume of A-shares reached 18224.48 billion yuan [1] Stocks Breaking Annual Line - A total of 118 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Jiaying Pharmaceutical (8.17%) - Kaiwang Technology (7.31%) - Chuanhuan Technology (6.60%) [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Jiaying Pharmaceutical: Today's increase of 9.96%, turnover rate of 5.15%, latest price at 7.40 yuan [1] - Kaiwang Technology: Today's increase of 15.65%, turnover rate of 8.96%, latest price at 38.87 yuan [1] - Chuanhuan Technology: Today's increase of 8.66%, turnover rate of 12.99%, latest price at 35.76 yuan [1] - Additional stocks with significant performance include: - Yongji Co. (6.07% deviation) - Runpu Food (5.64% deviation) - Kunlun Wanwei (5.37% deviation) [1]

Core Points - The Shanghai Composite Index closed at 3867.04 points, above the annual line, with an increase of 1.10% [1] - The total trading volume of A-shares reached 1.367165 trillion yuan [1] - A total of 74 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The stocks with the highest deviation rates include Hanxin Technology (10.28%), Jiaying Pharmaceutical (8.17%), and Runpu Food (6.44%) [1] - Other stocks that just crossed the annual line include ST Qibu, Yinghuatech, and Jiangxi Changyun, which have lower deviation rates [1] Trading Data - The trading performance of selected stocks shows significant daily changes, with Hanxin Technology leading with a daily increase of 13.96% and a turnover rate of 26.99% [1] - Jiaying Pharmaceutical and Runpu Food also showed strong daily increases of 9.96% and 9.35%, respectively [1] Additional Stock Information - Other notable stocks with positive performance include Yongji Co. (7.50%), Kaiwang Technology (13.86%), and Chuanhuan Technology (7.57%) [1] - The table lists various stocks with their respective trading data, including daily change percentages, turnover rates, annual line prices, latest prices, and deviation rates [1][2]

Market Overview - The traditional Chinese medicine sector experienced a decline of 0.28% on December 8, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Xinguang Pharmaceutical (300519) with a closing price of 17.34, up 3.96% and a trading volume of 131,800 shares, totaling 229 million yuan [1] - Kanghui Co., Ltd. (603139) closed at 22.35, up 2.48% with a trading volume of 20,300 shares, totaling 45.04 million yuan [1] - Conversely, Weikang Pharmaceutical (300878) saw a significant decline of 8.00%, closing at 22.66 with a trading volume of 110,800 shares, totaling 251 million yuan [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 723 million yuan from institutional investors, while retail investors saw a net inflow of 469 million yuan [2] - The capital flow for specific stocks showed: - Yunnan Baiyao (000538) had a net inflow of 26.56 million yuan from institutional investors, while retail investors had a net outflow of 6,450 yuan [3] - Kang Enbei (600572) reported a net inflow of 21.85 million yuan from institutional investors, with a net outflow of 1.92 million yuan from retail investors [3]